000650 仁和药业
2025/06 - 中期2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)4.6707.9229.66910.41812.814
总资产报酬率 ROA (%)3.7846.4577.5247.90010.018
投入资产回报率 ROIC (%)4.5157.7689.2729.89912.388

边际利润分析
销售毛利率 (%)36.59337.94037.12236.61737.975
营业利润率 (%)23.37319.01917.85818.49821.008
息税前利润/营业总收入 (%)23.35718.75617.36718.05619.838
净利润/营业总收入 (%)17.98613.90412.50813.80816.206

收益指标分析
经营活动净收益/利润总额(%)79.36592.002109.81599.10295.101
价值变动净收益/利润总额(%)5.80511.4558.4657.1763.040
营业外收支净额/利润总额(%)-0.106-0.0470.0250.029-0.243

偿债能力分析
流动比率 (X)5.6737.5746.1033.9344.187
速动比率 (X)5.2556.8095.5093.5413.566
资产负债率 (%)11.5569.04110.61415.88814.201
带息债务/全部投入资本 (%)4.2621.1071.5135.2613.552
股东权益/带息债务 (%)2,233.2938,878.1076,466.0671,785.7632,708.751
股东权益/负债合计 (%)689.127912.619758.439473.282538.965
利息保障倍数 (X)2,716.542-74.116-35.063-40.342-17.724

营运能力分析
应收账款周转天数 (天)39.39833.92926.85026.59026.496
存货周转天数 (天)61.17066.44651.44558.36562.718